<p><em><strong>交易集中化 VXM01 所有权和长期特许权经济于 OSRH 母公司层面</strong></em></p>
<p>OSR Holdings, Inc.（纳斯达克：OSRH）是一家专注于创新治疗和医疗技术的全球医疗控股公司，今天宣布已与 VAXIMM AG（&#34;Vaximm&#34;）签署了一项最终资产购买协议（&#34;APA&#34;），以总价 3000 万美元收购其全球知识产权组合及相关资产。</p>
<p>此次收购是 OSRH 之前宣布的与 BCM Europe AG（&#34;BCME&#34;）签署的 VXM01 全球独占许可协议的后续，协议中包括与该项目开发和商业化相关的高达 8.15 亿美元的里程碑付款。</p>
<p>根据 APA，OSRH 将收购完整的 VXM01 知识产权组合，包括：</p>
<ul>
<li>全球已授予和待授予的专利及专利申请</li>
</ul>
<ul>
<li>专有制造技术及相关工艺技术</li>
</ul>
<ul>
<li>监管文件和临床数据</li>
</ul>
<ul>
<li>生物材料</li>
</ul>
<ul>
<li>分配的项目相关合同和协议</li>
</ul>
<p>VXM01 知识产权组合包括在美国、加拿大、欧洲、日本、中国、韩国及其他地区的已授予和待授予的专利保护，保护期限延续至 2038 年。</p>
<p>&#34;此次收购推进了我们在 OSRH 母公司层面集中高价值知识产权资产的战略，&#34; OSRH 首席执行官 Peter Hwang 说。&#34;在我们的中心 - 辐射运营模式下，OSRH 作为中央知识产权所有者，而开发和商业化则通过附属实体和合作伙伴进行。这增强了许可灵活性和长期特许权经济，价值将归于 OSRH 股东。&#34;</p>
<p>如之前所披露，OSRH 于 2026 年 4 月 29 日与 BCME 签署了关于 VXM01 开发、商业化及潜在再许可的全球独占许可协议。根据该协议：</p>
<ul>
<li>OSRH 有资格获得高达 8.15 亿美元的开发和商业里程碑付款</li>
</ul>
<ul>
<li>BCME 将其全部无负担的 OSRH 股权作为里程碑义务的担保</li>
</ul>
<ul>
<li>OSRH 在 BCME 成本回收和优先回报阈值后保留 100% 的下游特许权经济权利</li>
</ul>
<ul>
<li>OSRH 持有一项 1500 万美元的卖出期权，行使价为每股 10.00 美元，自许可协议生效日期起六个月后开始行使。</li>
</ul>
<p>根据 APA 条款，3000 万美元的购买价格将在 BCME 许可协议下的第一个里程碑事件发生时支付，该事件定义为 VXM01 在胶质母细胞瘤（GBM）或胰腺导管腺癌（PDAC）中的 II 期临床研究（II 期 b 或等效试验待讨论）完成。该协议还允许 OSRH 在此类里程碑事件之前进行自愿部分付款。</p>
<p>集中化的知识产权所有权结构也可能促进未来对与 VXM01 平台相关的创新融资和特许权参与结构的评估，适时提供更多更新。</p>
<p><strong>关于 VXM01</strong></p>
<p>VXM01 是一种临床阶段的口服免疫疗法，针对 VEGFR-2，旨在诱导针对肿瘤血管的靶向免疫反应并调节肿瘤微环境。该项目在胶质母细胞瘤和胰腺癌的研究中显示出令人鼓舞的临床活性和免疫激活，这两种都是最难治疗的实体肿瘤。VXM01 由 Vaximm AG 开发，Vaximm AG 是 OSR Holdings 的全资子公司。</p>
<p><strong>关于 OSR Holdings</strong></p>
<p>OSR Holdings, Inc.（纳斯达克：OSRH）是一家全球医疗控股公司，致力于推动健康和保健领域的生物医学创新。通过其子公司，OSR Holdings 从事免疫肿瘤学、再生生物学和医疗设备技术，以改善全球健康结果。了解更多信息，请访问 www.OSR-Holdings.com</p>
<p><strong>投资者联系</strong></p>
<p>OSR Holdings, Inc.</p>
<p>投资者关系</p>
<p>ir@osr-holdings.com</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含适用证券法意义上的前瞻性声明，包括关于交易预期收益、里程碑付款、特许权经济、知识产权、与 VXM01 相关的未来开发和商业化活动，以及交易的预期战略和财务影响的声明。实际结果可能因各种风险和不确定性而有实质性差异，包括临床开发风险、监管风险、融资风险、商业化风险以及公司向美国证券交易委员会提交的文件中描述的其他因素。除法律要求外，公司不承担更新前瞻性声明的义务。</p>
<p><strong>来源：</strong> OSR Holdings, Inc.</p>
<p>查看原始新闻稿，请访问 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE3MDkzNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE3MDkzNQ"/></p>

OSRH

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

基因改革 ETF - ARK

生物科技 ETF - VanEck Vectors

<p>OSR Holdings, Inc.（纳斯达克代码：OSRH）以 3000 万美元收购了 VAXIMM AG 的全部 VXM01 知识产权组合。此次收购集中化了所有权，并增强了长期的特许权使用费经济效益。该交易是在与 BCM Europe AG 达成的先前许可协议之后进行的，该协议包括高达 8.15 亿美元的潜在里程碑付款。VXM01 项目针对难以治疗的肿瘤，预计将改善许可灵活性和股东价值</p>

<p><em><strong>Transaction Centralizes VXM01 Ownership and Long-Term Royalty Economics at the OSRH Parent Level</strong></em></p>
<div class="lb-trans"><p><em><strong>交易集中化 VXM01 所有权和长期特许权经济于 OSRH 母公司层面</strong></em></p>
</div><p>OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company focused on innovative therapeutics and healthcare technologies, today announced it has entered into a definitive Asset Purchase Agreement (&#34;APA&#34;) with VAXIMM AG (&#34;Vaximm&#34;) to acquire the full global intellectual property portfolio and related assets for an aggregate purchase price of $30 million.</p>
<div class="lb-trans"><p>OSR Holdings, Inc.（纳斯达克：OSRH）是一家专注于创新治疗和医疗技术的全球医疗控股公司，今天宣布已与 VAXIMM AG（&#34;Vaximm&#34;）签署了一项最终资产购买协议（&#34;APA&#34;），以总价 3000 万美元收购其全球知识产权组合及相关资产。</p>
</div><p>The acquisition follows OSRH's previously announced definitive global exclusive license agreement with BCM Europe AG (&#34;BCME&#34;) for VXM01, which includes up to $815 million in milestone payments tied to the development and commercialization of the program.</p>
<div class="lb-trans"><p>此次收购是 OSRH 之前宣布的与 BCM Europe AG（&#34;BCME&#34;）签署的 VXM01 全球独占许可协议的后续，协议中包括与该项目开发和商业化相关的高达 8.15 亿美元的里程碑付款。</p>
</div><p>Under the APA, OSRH will acquire the complete VXM01 intellectual property portfolio, including:</p>
<div class="lb-trans"><p>根据 APA，OSRH 将收购完整的 VXM01 知识产权组合，包括：</p>
</div><ul>
<li>Global issued and pending patents and patent applications</li>
</ul>
<div class="lb-trans"><ul>
<li>全球已授予和待授予的专利及专利申请</li>
</ul>
</div><ul>
<li>Proprietary manufacturing know-how and related process technology</li>
</ul>
<div class="lb-trans"><ul>
<li>专有制造技术及相关工艺技术</li>
</ul>
</div><ul>
<li>Regulatory filings and clinical data</li>
</ul>
<div class="lb-trans"><ul>
<li>监管文件和临床数据</li>
</ul>
</div><ul>
<li>Biological materials</li>
</ul>
<div class="lb-trans"><ul>
<li>生物材料</li>
</ul>
</div><ul>
<li>Assigned program-related contracts and agreements</li>
</ul>
<div class="lb-trans"><ul>
<li>分配的项目相关合同和协议</li>
</ul>
</div><p>The VXM01 IP portfolio includes issued and pending patent protection across major global jurisdictions including the United States, Canada, Europe, Japan, China, Korea, and additional territories, with protection extending into 2038.</p>
<div class="lb-trans"><p>VXM01 知识产权组合包括在美国、加拿大、欧洲、日本、中国、韩国及其他地区的已授予和待授予的专利保护，保护期限延续至 2038 年。</p>
</div><p>&#34;This acquisition advances our strategy of centralizing high-value intellectual property assets at the OSRH parent level,&#34; said Peter Hwang, CEO of OSRH. &#34;Under our hub-and-spoke operating model, OSRH acts as the central IP owner, while development and commercialization are executed through affiliated entities and partners. This enhances licensing flexibility and long-term royalty economics, with value accruing to OSRH shareholders.&#34;</p>
<div class="lb-trans"><p>&#34;此次收购推进了我们在 OSRH 母公司层面集中高价值知识产权资产的战略，&#34; OSRH 首席执行官 Peter Hwang 说。&#34;在我们的中心 - 辐射运营模式下，OSRH 作为中央知识产权所有者，而开发和商业化则通过附属实体和合作伙伴进行。这增强了许可灵活性和长期特许权经济，价值将归于 OSRH 股东。&#34;</p>
</div><p>As previously disclosed, OSRH entered into a definitive global exclusive license agreement with BCME on April 29, 2026 relating to the development, commercialization and potential sublicensing of VXM01. Under the agreement:</p>
<div class="lb-trans"><p>如之前所披露，OSRH 于 2026 年 4 月 29 日与 BCME 签署了关于 VXM01 开发、商业化及潜在再许可的全球独占许可协议。根据该协议：</p>
</div><ul>
<li>OSRH is eligible to receive up to $815 million in development and commercial milestone payments</li>
</ul>
<div class="lb-trans"><ul>
<li>OSRH 有资格获得高达 8.15 亿美元的开发和商业里程碑付款</li>
</ul>
</div><ul>
<li>BCME pledged its entire unencumbered OSRH equity stake as collateral for milestone obligations</li>
</ul>
<div class="lb-trans"><ul>
<li>BCME 将其全部无负担的 OSRH 股权作为里程碑义务的担保</li>
</ul>
</div><ul>
<li>OSRH retains rights to 100% of downstream royalty economics following BCME cost recovery and preferred return thresholds</li>
</ul>
<div class="lb-trans"><ul>
<li>OSRH 在 BCME 成本回收和优先回报阈值后保留 100% 的下游特许权经济权利</li>
</ul>
</div><ul>
<li>OSRH holds a $15 million put option exercisable at $10.00 per share beginning six months after the licensing agreement effective date.</li>
</ul>
<div class="lb-trans"><ul>
<li>OSRH 持有一项 1500 万美元的卖出期权，行使价为每股 10.00 美元，自许可协议生效日期起六个月后开始行使。</li>
</ul>
</div><p>Under the terms of the APA, the $30 million purchase price becomes payable upon the first milestone event under the BCME License Agreement, defined as completion of a Phase 2 clinical study (Phase 2b or equivalent trial pending discussions) of VXM01 in either glioblastoma (GBM) or pancreatic ductal adenocarcinoma (PDAC). The agreement also permits OSRH to make voluntary partial payments prior to such milestone event.</p>
<div class="lb-trans"><p>根据 APA 条款，3000 万美元的购买价格将在 BCME 许可协议下的第一个里程碑事件发生时支付，该事件定义为 VXM01 在胶质母细胞瘤（GBM）或胰腺导管腺癌（PDAC）中的 II 期临床研究（II 期 b 或等效试验待讨论）完成。该协议还允许 OSRH 在此类里程碑事件之前进行自愿部分付款。</p>
</div><p>The centralized IP ownership structure may also facilitate future evaluation of innovative financing and royalty participation structures associated with the VXM01 platform, with additional updates provided as appropriate.</p>
<div class="lb-trans"><p>集中化的知识产权所有权结构也可能促进未来对与 VXM01 平台相关的创新融资和特许权参与结构的评估，适时提供更多更新。</p>
</div><p><strong>About VXM01</strong></p>
<div class="lb-trans"><p><strong>关于 VXM01</strong></p>
</div><p>VXM01 is a clinical-stage oral immunotherapy targeting VEGFR-2, designed to induce a targeted immune response against tumor vasculature and modulate the tumor microenvironment. The program has demonstrated encouraging clinical activity and immune activation in studies in glioblastoma and pancreatic cancer, two of the most difficult to treat solid tumors. VXM01 is being developed by Vaximm AG, a wholly owned subsidiary of OSR Holdings.</p>
<div class="lb-trans"><p>VXM01 是一种临床阶段的口服免疫疗法，针对 VEGFR-2，旨在诱导针对肿瘤血管的靶向免疫反应并调节肿瘤微环境。该项目在胶质母细胞瘤和胰腺癌的研究中显示出令人鼓舞的临床活性和免疫激活，这两种都是最难治疗的实体肿瘤。VXM01 由 Vaximm AG 开发，Vaximm AG 是 OSR Holdings 的全资子公司。</p>
</div><p><strong>About OSR Holdings</strong></p>
<div class="lb-trans"><p><strong>关于 OSR Holdings</strong></p>
</div><p>OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Holdings engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.com</p>
<div class="lb-trans"><p>OSR Holdings, Inc.（纳斯达克：OSRH）是一家全球医疗控股公司，致力于推动健康和保健领域的生物医学创新。通过其子公司，OSR Holdings 从事免疫肿瘤学、再生生物学和医疗设备技术，以改善全球健康结果。了解更多信息，请访问 www.OSR-Holdings.com</p>
</div><p><strong>Investor Contact</strong></p>
<div class="lb-trans"><p><strong>投资者联系</strong></p>
</div><p>OSR Holdings, Inc.</p>
<div class="lb-trans"><p>OSR Holdings, Inc.</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>ir@osr-holdings.com</p>
<div class="lb-trans"><p>ir@osr-holdings.com</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the anticipated benefits of the transaction, milestone payments, royalty economics, intellectual property rights, future development and commercialization activities relating to VXM01, and the anticipated strategic and financial impact of the transaction. Actual results may differ materially due to various risks and uncertainties, including clinical development risks, regulatory risks, financing risks, commercialization risks and other factors described in the Company's filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by law.</p>
<div class="lb-trans"><p>本新闻稿包含适用证券法意义上的前瞻性声明，包括关于交易预期收益、里程碑付款、特许权经济、知识产权、与 VXM01 相关的未来开发和商业化活动，以及交易的预期战略和财务影响的声明。实际结果可能因各种风险和不确定性而有实质性差异，包括临床开发风险、监管风险、融资风险、商业化风险以及公司向美国证券交易委员会提交的文件中描述的其他因素。除法律要求外，公司不承担更新前瞻性声明的义务。</p>
</div><p><strong>SOURCE:</strong> OSR Holdings, Inc.</p>
<div class="lb-trans"><p><strong>来源：</strong> OSR Holdings, Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新闻稿，请访问 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE3MDkzNQ" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1170935"/></p>

OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction | OSRH Stock News

StockTitan

OSR HOLDINGS INC C/WTS 09/02/2028 (TO PUR COM)

OSR Holdings 以 3000 万美元的交易收购了 VXM01 的完整知识产权组合 | OSRH 股票新闻